Align Financial’s Regeneron Pharmaceuticals REGN Stock Holding History

Align Financial’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$758	Buy	+1	New	+$756	﹤0.01%	430

Other funds holding REGN

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Pinnacle Associates New York $8.92B AUM 43.91% 1-Year Est. Return

GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return

Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Wedge Capital Management Charlotte, North Carolina $5.72B AUM 38.26% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Bellecapital Zurich, Switzerland $683M AUM 33.2% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

Align Financial's REGN Position: Q3 2026 in Review

Align Financial opened a new position in Regeneron Pharmaceuticals (REGN) in Q3 2026: 1 share worth $758. The stake represents ﹤0.01% of the portfolio and ranks #430 among its holdings.

252 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

Align Financial held 1 share of Regeneron Pharmaceuticals worth $758 as of Q3 2026.
Regeneron Pharmaceuticals was a new Align Financial position in Q3 2026.
Regeneron Pharmaceuticals made up ﹤0.01% of Align Financial's portfolio in Q3 2026, its #430 holding.
252 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Align Financial's 13F filing for Q3 2026, filed 16 Oct 2026.